Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Trial Profile

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camptothecin (Primary) ; Bevacizumab
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Cerulean Pharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Sep 2017 Results assessing safety and efficacy of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma, were published in the Annals of Oncology.
    • 17 Aug 2016 According to a Cerulean Pharma media release, the full data set from the trial are expected to be submitted for presentation at an upcoming medical conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top